{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:13Z","timestamp":1793163313258,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01529-5","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:42:40Z","timestamp":1761583360000},"page":"3547-3560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Varitsara","family":"Mangkorntongsakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saxon D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","volume":"64","author":"JL Harden","year":"2015","unstructured":"Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66\u201373.","journal-title":"J Autoimmun"},{"key":"1529_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","volume":"26","author":"K Reich","year":"2012","unstructured":"Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1529_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","volume":"270","author":"O Ahlehoff","year":"2011","unstructured":"Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147\u201357.","journal-title":"J Intern Med"},{"issue":"3","key":"1529_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar R, Shin D, Neimann A, Troxel A, Gelfand J. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol. 2010;163(3):586\u201392.","journal-title":"Br J Dermatol"},{"key":"1529_CR5","doi-asserted-by":"publisher","unstructured":"Jindal S, Jindal N. Psoriasis and cardiovascular diseases: a literature review to determine the causal relationship. Cureus. 2018;10(2):e2195. https:\/\/doi.org\/10.7759\/cureus.2195.","DOI":"10.7759\/cureus.2195"},{"issue":"10","key":"1529_CR6","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/ijms18102211","volume":"18","author":"SC-S Hu","year":"2017","unstructured":"Hu SC-S, Lan C-CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1529_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721\u20138.","journal-title":"Cardiovasc Res"},{"issue":"18","key":"1529_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016956","volume":"9","author":"S Karbach","year":"2020","unstructured":"Karbach S, Hobohm L, Wild J, et al. Impact of psoriasis on mortality rate and outcome in myocardial infarction. J Am Heart Assoc. 2020;9(18):e016956.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1529_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1759720X15591801","volume":"7","author":"L Eder","year":"2015","unstructured":"Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187\u201395.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1529_CR10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","volume":"9","author":"G Caiazzo","year":"2018","unstructured":"Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668.","journal-title":"Front Immunol"},{"issue":"6","key":"1529_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1529_CR12","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","volume":"156","author":"F Poizeau","year":"2020","unstructured":"Poizeau F, Nowak E, Kerbrat S, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody ustekinumab. JAMA Dermatol. 2020;156(11):1208\u201315.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1529_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","volume":"176","author":"W Rungapiromnan","year":"2017","unstructured":"Rungapiromnan W, Yiu Z, Warren R, Griffiths C, Ashcroft D. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890\u2013901.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1529_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol"},{"key":"1529_CR15","doi-asserted-by":"crossref","unstructured":"Bro\u017cek J, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669\u201377.","DOI":"10.1111\/j.1398-9995.2009.01973.x"},{"key":"1529_CR16","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Wiley, Hoboken, 2019.","DOI":"10.1002\/9781119536604"},{"issue":"28","key":"1529_CR17","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1002\/sim.6301","volume":"33","author":"AC Brockhaus","year":"2014","unstructured":"Brockhaus AC, Bender R, Skipka G. The Peto odds ratio viewed as a new effect measure. Stat Med. 2014;33(28):4861\u201374.","journal-title":"Stat Med"},{"issue":"4","key":"1529_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"J Bagel","year":"2017","unstructured":"Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1529_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1529_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1529_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1529_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1529_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","volume":"31","author":"L Cai","year":"2017","unstructured":"Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1529_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"2","key":"1529_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1529_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598\u2013606.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1529_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1067\/mjd.2003.307","volume":"48","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6):829\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1529_CR28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","volume":"165","author":"AB Gottlieb","year":"2011","unstructured":"Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):652\u201360.","journal-title":"Br J Dermatol"},{"key":"1529_CR29","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627\u201332 (discussion 32).","DOI":"10.1001\/archderm.139.12.1627"},{"issue":"9993","key":"1529_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"3","key":"1529_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","volume":"39","author":"A Igarashi","year":"2012","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study G. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol. 2012;39(3):242\u201352.","journal-title":"J Dermatol"},{"issue":"6","key":"1529_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580\u201392.","journal-title":"N Engl J Med"},{"issue":"4","key":"1529_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"14","key":"1529_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"13","key":"1529_CR35","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190\u20139.","journal-title":"N Engl J Med"},{"issue":"9625","key":"1529_CR36","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665\u201374.","journal-title":"Lancet"},{"issue":"1","key":"1529_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44\u201352.","journal-title":"J Dermatol Sci"},{"issue":"8","key":"1529_CR38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"issue":"9","key":"1529_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053\u201362.","journal-title":"J Dermatol"},{"issue":"4","key":"1529_CR40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930\u20139.","journal-title":"Br J Dermatol"},{"issue":"16","key":"1529_CR41","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"issue":"2","key":"1529_CR42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412\u201321.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1529_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1529_CR44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10201","key":"1529_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"10198","key":"1529_CR46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"10091","key":"1529_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"3","key":"1529_CR48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","volume":"165","author":"BE Strober","year":"2011","unstructured":"Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1529_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154\u201363.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"1529_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1529_CR51","first-page":"166","volume":"12","author":"X Zhu","year":"2013","unstructured":"Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166\u201374.","journal-title":"J Drugs Dermatol"},{"issue":"10273","key":"1529_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475\u201386.","journal-title":"Lancet"},{"issue":"2","key":"1529_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"10273","key":"1529_CR54","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"2","key":"1529_CR55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"1529_CR56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"10","key":"1529_CR57","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","volume":"152","author":"KF Hjuler","year":"2016","unstructured":"Hjuler KF, B\u00f8ttcher M, Vestergaard C, B\u00f8tker HE, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152(10):1114\u201321.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1529_CR58","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","volume":"2","author":"AK Dey","year":"2017","unstructured":"Dey AK, Joshi AA, Chaturvedi A, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography\/computed tomography. JAMA Cardiol. 2017;2(9):1013\u20138.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1529_CR59","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2011.1211","volume":"306","author":"C Ryan","year":"2011","unstructured":"Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864\u201371.","journal-title":"JAMA"},{"key":"1529_CR60","doi-asserted-by":"crossref","unstructured":"Hodkinson A, Kontopantelis E. Applications of simple and accessible methods for meta-analysis involving rare events: a simulation study. Stat Methods Med Res. 2021;30(7):1589\u2013608.","DOI":"10.1177\/09622802211022385"},{"issue":"10","key":"1529_CR61","first-page":"1002","volume":"16","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Kerdel F, Naldi L, et al. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol. 2017;16(10):1002\u201313.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1529_CR62","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jdv.12768","volume":"29","author":"O Ahlehoff","year":"2015","unstructured":"Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1529_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322849","volume":"20","author":"X Zhong","year":"2025","unstructured":"Zhong X, Luo J, Huang Y, Wang S, Huang Y. Cardiovascular safety of Janus kinase inhibitors: a pharmacovigilance study from 2012\u20132023. PLoS ONE. 2025;20(5):e0322849. https:\/\/doi.org\/10.1371\/journal.pone.0322849.","journal-title":"PLoS ONE"},{"key":"1529_CR64","doi-asserted-by":"publisher","unstructured":"Lluch-Galcer\u00e1 JJ, Carrascosa J-M, Gonz\u00e1lez-Quesada A, et al. Cardiovascular safety of systemic psoriasis treatments: a prospective cohort study in the BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20705.","DOI":"10.1111\/jdv.20705"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01529-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:02:56Z","timestamp":1763200976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01529-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01529-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Saxon D Smith has been an advisor for and\/or received speaking fees from and\/or served as an investigator in clinical trials for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Janssen Cilag, Leo Pharma, Novartis, Pfizer, Sanofi Genzyme and UCB. Annika Smith has been an advisor for and\/or received speaking fees from and\/or served as an investigator in clinical trials for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Janssen Cilag, Leo Pharma, Novartis, Pfizer, Sunpharma and UCB. Annika D Smith serves on the Editorial Advisory Board of\n                      Dermatology and Therapy\n                      , but had no involvement in the editorial review or decision-making process for the present manuscript. Varitsara Mangkorntongsakul, Joseph S Joseph, James P Pham and Clara K Chow declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This systematic review was conducted in accordance with ethical guidelines for conducting literature reviews. No primary data were collected for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}